Background
==========

According to the World Health Organization (WHO), the most common cancer among women is breast cancer, which globally represents 29% of all female cancers. It is estimated that, each year, 1.38 million new cases are detected and 450,000 die from this disease.[@b1-ijn-13-1081]

Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology.[@b1-ijn-13-1081]--[@b5-ijn-13-1081] Most women with early-stage breast cancer are treated with surgery combined with other treatments (radiation, chemotherapy, and hormonal therapy) to reduce the risk of recurrence.[@b2-ijn-13-1081]--[@b5-ijn-13-1081]

Patients with metastatic disease are primarily treated with a systemic approach based on primary tumor characteristics, such as tumor size, grade, number of involved lymph nodes, the status of estrogen (ER) and progesterone (PR) receptors, and the expression of the human epidermal growth factor receptor 2 (HER2).[@b3-ijn-13-1081]--[@b6-ijn-13-1081] Molecular portraits of breast cancer have been used to determine treatment and prognosis after medical diagnosis.[@b6-ijn-13-1081],[@b7-ijn-13-1081]

Metal nanoparticles, including AgNPs, have attracted much attention due to their wide variety of applications in medicine and other sciences.[@b8-ijn-13-1081] AgNPs have been used in some biological processes (eg, antibacterial, remediation environmental, therapeutic devices). A number of organic materials are known to work as protective agents for preventing colloid sintering during the synthesis of AgNPs; polyvinylpyrrolidone (PVP) is one of the most widely used agents to this purpose, and acts by controlling the reduction rate of silver ions.[@b9-ijn-13-1081] In reactions where alcohol and ethylene glycol are used, PVP works as a stabilizing agent to ensure dispersion of very small metal particles.[@b10-ijn-13-1081] Recently, the use of AgNPs as anticancer agents has been promising.[@b11-ijn-13-1081] Furthermore, AgNPs have been used in several cancer cells types (eg, colon and cervical cancers, human lung carcinoma).[@b11-ijn-13-1081]--[@b13-ijn-13-1081] Although induction of oxidative stress by AgNPs and impairment of DNA repair mechanisms have been observed as a general mode of toxicity, their mechanisms of action are still unclear.[@b11-ijn-13-1081],[@b14-ijn-13-1081] The aim of this study was to evaluate adhesion, proliferation, and apoptosis in different molecular portraits of breast cancer treated with AgNPs as well as its pathway--network analysis.

Materials and methods
=====================

All experiments were conducted in triplicate as independent samples. [Figure 1](#f1-ijn-13-1081){ref-type="fig"} summarizes the workflow and approach of this study -- from sample characterization to the biological and pathway--network analyses.

Characterization of cell lines
------------------------------

The selection of breast cancer cell lines (MCF7, HCC1954, and HCC70) was done according to their molecular portrait.[@b6-ijn-13-1081] All cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). MCF7 (ATCC^®^ HTB-22) is an epithelial-adherent adenocarcinoma cell line obtained from a 69-year-old Caucasian female that expresses ERs and PRs and is HER2/neu-negative, classified as luminal A. HCC1974 (ATCC^®^ CRL 2338) is an epithelial-adherent ductal carcinoma cell line obtained from a 61-year-old Indian female classified as HER2/neu, negative for estrogen and progesterone receptors. HCC70 (ATCC^®^ CRL-2315™) is an epithelial-adherent cell line derived from the primary ductal carcinoma of a 49-year-old Black female that is negative for estrogen and progesterone receptors, and is classified as a triple-negative HER2/neu. All cell lines were stored in the vapor phase of liquid nitrogen.

Synthesis and characterization of colloidal AgNPs
-------------------------------------------------

AgNP solutions were prepared using 100 mg silver nitrate (AgNO~3~) in 100 mL ethanol and 1 g PVP as the stabilizing agent; the weight ratio of PVP to AgNO~3~ was kept at 10:1. The ethanolic solution containing the metallic salt and PVP was refluxed to 363 K and stirred for 12 hours. The formation of AgNPs can be observed at a glance by a change in color in the solution, because small AgNPs are amber and the addition of PVP prevents aggregation.[@b10-ijn-13-1081] We obtained the ratio 1:10 (AgNO~3~/PVP) that was best for stabilization of AgNP size. When we increased the PVP concentration, the particle nucleation rate was higher and particle size decreased.[@b15-ijn-13-1081] The complete methodology for preparation of AgNPs can be obtained from a previous work.[@b16-ijn-13-1081] The characterization of AgNPs was undertaken by ultraviolet-visible (UV--Vis) spectrophotometry and transmission electron microscopy (TEM). [Figure 2A](#f2-ijn-13-1081){ref-type="fig"} shows an absorption peak at 412 nm UV--Vis, which indicates the presence of Ag ions in the sample. On the other hand, [Figure 2B and C](#f2-ijn-13-1081){ref-type="fig"} indicate the presence and size of particles (2--9 nm) in the sample by TEM image and histogram.

Exposure to AgNPs
-----------------

Breast cancer cell lines were adjusted to a concentration of 1×10^5^/mL in RPMI-1640 medium (Thermo Fisher Scientific, Waltham, MA, USA), for HCC1954 and HCC70, and DMEM medium, (Thermo Fisher Scientific), for the MCF7 cell line. Plates were incubated at 37°C with 95% relative humidity and 5% CO~2~ atmosphere for 24 hours. Then, the AgNPs groups were exposed to a concentration of 12.5 µg/mL of nanoparticles for 24 hours. In control groups, the same conditions were used but without AgNPs. All in vitro tests were conducted under these conditions, with the exception of the real-time adhesion analysis. To observe the adhesion, it was necessary to expose cells to the absence/presence of AgNPs during culture.

Adhesion analysis in real time
------------------------------

Cell adhesion was analyzed in triplicate in independent samples of each cell line in the absence/presence of AgNPs. In total, 1×10^5^ cells were cultured in a 96-well plate containing microelectrodes for the measurement of cell number, which is translated into a value called the cellular index. This value determines how much a cell disrupts flow impedance in real time using the xCELLingence system (Roche Applied Sciences and ACEA Biosciences, Basel, Switzerland). The cellular index was analyzed every 3 hours for 24 hours post-treatment with AgNPs.

Proliferation and viability assay
---------------------------------

Proliferation and viability percentages were obtained by a modification of the original Mossman technique.[@b17-ijn-13-1081],[@b18-ijn-13-1081] Cells were incubated for 24 hours in the presence/absence of AgNPs; then, MTT (Sigma-Aldrich, St Louis, MO, USA) was added and allowed to incubate for 2 hours, and, finally, extraction buffer (20% sodium dodecyl sulfate, Sigma-Aldrich) and 50% dimethylformamide (Sigma-Aldrich) were added. The plate was incubated for 24 hours and read at 570/630 nm in an enzyme-linked immunosorbent assay reader (Synergy HT Multi-Mode Microplate Reader, with the Gen5 v2.0; BioTek, Winooski, VT, USA). The result of this assay was expressed as the proliferation index, calculated as the optical densities in stimulated cells divided by the optical densities of cells without stimulation, of each cell line.

Determination of apoptosis
--------------------------

After AgNPs stimulation, cells were washed twice with phosphate-buffered saline (PBS) and 5 µL fluorescein isothiocyanate-Annexin V was added. Cells were incubated for 15 minutes; then, 5 µL propidium iodide was added to evaluate apoptosis by a detection kit (BD Pharmigen, San Diego, CA, USA). Finally, apoptosis was measured on an EPICS XL-MCL Flow Cytometer (Beckman Coulter, Krefeld, Germany), and apoptosis results were expressed as the percentage of total apoptosis.

Nucleic acid isolation
----------------------

Isolation of DNA and RNA was done with the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany) from almost a million of cells of each cell line in the absence/presence of AgNPs. After isolation, RNA quality was measured with an RNA 6000 Nano kit (Agilent, Santa Clara, CA, USA) in 2100 Bioanalyzer (Agilent). The acceptable RNA Integrity Number (RIN) was higher than 6.0. We quantified RNA and DNA with a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Acceptable quality DNA should have 260/280 nm ratios 1.8 and 2.0.

Labeling and hybridization
--------------------------

In total, 200 ng total RNA from cell lines was amplified and labeled using the Low Input Two-Color Quick Amp Labeling Kit (Agilent). As internal controls, a Two-Color RNA Spike-In Kit (Agilent) was used. Labeled samples were purified with the RNeasy mini kit (Qiagen, Hilden, Germany). Cell line samples were labeled with Cy5 dye, and a control was labeled with Cy3 dye.

Hybridization was done with a Hi-RPM Gene Expression Hybridization Kit (Agilent) in a Human GE 4×44k v2 microarray AMADID 026652 (Agilent).

Microarray data
---------------

The hybridized microarray was scanned with a DNA Microarray Scanner with SureScan High-Resolution Technology, C version (Agilent), and a Feature Extraction software v.11 (Agilent) was used to extract microarray data. Cy3/Cy5 log rates from a gene panel were analyzed in the R Package. Afterwards, we selected genes highly associated with adhesion, proliferation, and apoptosis. We obtained 437 genes, which were processed as follows: data were filtered and nested in centroids using Gene Cluster 3.0 and then adjusted to logarithm base 2; thereafter, genes were centered on the basis of the mean. Heat maps of these genes were generated in the Java program Treeview 1.1.6r2.

Probabilistic Graphical Model impact analysis
---------------------------------------------

The 437 selected genes were analyzed using the probabilistic graphical model (PGM) based on the Markov random field in Reactome FIViz, a Cytoscape plugin (<http://www.cytoscape.org/download.php>, and this one of ReactomeFIViz \[also called Reactome Cytoscape Plugin or ReactomeFIPlugIn\] <http://apps.cytoscape.org/apps/reactomefiplugin>),[@b14-ijn-13-1081],[@b19-ijn-13-1081],[@b20-ijn-13-1081] where an interactome was generated with the top 10% differences.[@b21-ijn-13-1081] Then, we ran a network clustering algorithm on the interactome to identify working subnetworks.[@b20-ijn-13-1081] The tool provides predicted functional impact scores by integrating all observed variations to assess whether the activities of each gene are increased, decreased, or unaffected.[@b14-ijn-13-1081],[@b19-ijn-13-1081],[@b20-ijn-13-1081]

Pathway enrichment analysis
---------------------------

The gene modules were subjected to pathway enrichment analyses (hypergeometric testing);[@b22-ijn-13-1081] then, pathway functional annotations were conducted using the Reactome FIViz, a Cytoscape plugin.

PGM pathway analysis
--------------------

Pathways related to adhesion, proliferation, and apoptosis were analyzed with the PARADIGM; this approach was adapted for Reactome pathways by converting reactions drawn in pathway diagrams into factors; a PGM used in the Reactome FIViz, a Cytoscape plugin.[@b19-ijn-13-1081],[@b23-ijn-13-1081] This was done according to Reactome pathways database and by using their pathways component names in order to analyze the integrated pathway activity (IPA) in each related pathway.

Statistical analysis
--------------------

Independent samples were analyzed with Student's *t*-test and the Mann--Whitney *U* test, according to the nature of the variable. Statistical significance was set at *p*-value ≤0.05. Assessment of pathway associations was undertaken by the hypergeometric test using the Benjamini--Hochberg false discovery rate (FDR) correction, with an FDR correction-modified *p*-value ≤0.05. The analyses were conducted with SPSS version 20 (SPSS, Chicago, IL, USA).

Results
=======

Adhesion in real time
---------------------

To investigate whether AgNPs had any effect on the ability of cancer cells to adhere and grow, cells were seeded in plates under conditions as explained earlier. Significant decreases in adhesion were observed with AgNPs treatment; the lowest values recorded were for the MCF7 line followed by the HCC70 cell line, as shown in [Figure 3A and C](#f3-ijn-13-1081){ref-type="fig"}. The first 9 hours of the real-time assay show direct changes in cell adhesion of the treated lines against the controls. MCF7 and HCC70 lines show pronounced decrease compared to the control, whereas the decrease in HCC1954 line is less ([Figure 3B](#f3-ijn-13-1081){ref-type="fig"}). However, the cellular index from 12 hours onwards decreases steadily in all the lines and is maintained until 24 hours.

Proliferation and viability
---------------------------

After 24 hours of exposure to the AgNPs, proliferation ([Figure 4](#f4-ijn-13-1081){ref-type="fig"}) was measured in each of the cell lines with the MTT assay. MCF7 and HCC70 showed a significant reduction between the AgNPs group and control group; both lines exhibited a reduction of more than half in the proliferation index. Whereas HCC1954 had a moderate reduction as in the adhesion assay; HCC1954 was least affected by AgNPs.

Determination of apoptosis
--------------------------

The total apoptosis percentage was determined in each of the cell lines exposed and not exposed to AgNPs ([Figure 5A](#f5-ijn-13-1081){ref-type="fig"}). [Figure 5B--D](#f5-ijn-13-1081){ref-type="fig"} shows a representative dot plot of each cell line exposed to AgNPs. All cell lines showed a significant increase in the percentage of apoptosis; HCC70 showed the highest percentage of apoptosis. The increase in percentage is at least five times greater in comparison to the respective controls of each cell line.

Gene expression
---------------

A gene expression microarray assay was conducted for HCC70, HCC1954, and MCF7 cell lines. Both control and AgNP-treated cells were tested. [Figure 6](#f6-ijn-13-1081){ref-type="fig"} shows the heat map of the expression of 437 genes in each of the different lines of breast cancer. The expression of different genes change in response to the exposure to AgNPs; these changes differ according to the conditions of the original cell (the list of the 437 genes, as well as their expression data, are included in the [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=152237.xlsx)).

PGM impact analysis
-------------------

We generated an interactome from the 437 genes along with their immediate inferred interaction partners; this provided a network of 12,177 genes. The top 10% of nodes, classified by differences in protein impact score (PIS) were selected to generate a minimal essential network (MEN; [Figure 7](#f7-ijn-13-1081){ref-type="fig"}).[@b21-ijn-13-1081] The size of the nodes in the interactome is proportional to their PIS; this value is obtained not only by the expression of the gene but also by their known interactions.[@b14-ijn-13-1081],[@b19-ijn-13-1081] It is important to mention that the app generates a comparison against random samples from its database in order to provide the results. The edges show the interactions between different nodes in the interactome. [Table 1](#t1-ijn-13-1081){ref-type="table"} shows the PIS of the top 10% of the genes and their *p*-value against random samples, according to the PGM impact analysis. Genes such as cyclin B2 (*CCNB2*), laminin subunit alpha 1 (*LAMA1*), matrix metallopeptidase 7 (*MMP7*), secreted protein acidic and cysteine-rich (*SPARC*), *CDC28* protein kinase regulatory subunit 2 (*CKS2*), aurora kinase B (*AURKB*), interleukin 18 (*IL18*), versican (*VCAN*), and matrix metallopeptidase 3 (*MMP3*) were some of the genes that showed statistically significant gene expression from the random samples generated dynamically by the App in the control lines. Meanwhile, in the AgNPs groups, genes that were found to be differently expressed were the *MMP3*, *SPARC*, thrombospondin 2 (*THBS2*), occludin (*OCLN*), lipoprotein lipase (*LPL*), interleukin 1 beta (*IL1B*), serpin peptidase inhibitor, clade F member 1 (*SERPINF1*), cadherin 1 (*CDH1*), mutL homolog 1 (*MLH1*), collagen type VI alpha 1 chain (*COL6A1*), connective tissue growth factor (*CTGF*), tumor necrosis factor receptor superfamily member 1A-associated via death domain (*TRAF2*), and cadherin 6 (*CDH6*), compared to a random background generated dynamically by the App.

The MEN includes 122 genes and 246 edges cluster by modularity;[@b20-ijn-13-1081] eight modules were identified and mapped onto biological pathways using the Reactome FIViz, a Cytoscape plugin, to ascertain function as shown in [Table 2](#t2-ijn-13-1081){ref-type="table"} (the complete data of [Table 2](#t2-ijn-13-1081){ref-type="table"} is shown in the [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=152237.xlsx)). [Table 2](#t2-ijn-13-1081){ref-type="table"} shows that gene sets are significant for adhesion (extracellular matrix organization, focal adhesion, and integrin signaling pathway), proliferation (cell cycle, anaphase-promoting complex \[APC/C\] mediated degradation of cell-cycle proteins), and apoptosis (direct p53 effectors, the intrinsic pathway for apoptosis, and p53 signaling pathway).

PGM pathway analysis
--------------------

The results of the PGM pathway analysis are shown in [Table 3](#t3-ijn-13-1081){ref-type="table"} (the complete data of [Table 3](#t3-ijn-13-1081){ref-type="table"} is shown in the [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=152237.xlsx)), where functional components of related pathways are displayed by biological activities (adhesion, proliferation, and apoptosis) and the IPA differences in values. There were several significant changes related to the functional components on adhesion, which included the secreted phosphoprotein 1-CD44 antigen (SPP1-CD44), platelet endothelial cell adhesion molecule 1 (PECAM1), SPP1, SPP1-Integrin alpha5beta1-alpha9beta1, SPP1-Integrin alphaVBeta1,3,5, Integrin alphaVbeta3-PECAM1, Integrin alphaVbeta3-Tenascin, Tenascin-C hexamer, and Integrin alpha9beta1-Tenascin-C hexamer. There were no significant changes related to functional components of apoptosis and proliferation. Some components of the apoptosis pathways, such as caspase-8 (CASP8) and catenin beta-1 (CTNNB1), reached significant *p*-values, but not FDR values, which indicate probable false positives.

Discussion
==========

The use of nanomaterials in medicine has been an important contribution to science; however, the biological risk of using AgNPs has not been clearly established.[@b24-ijn-13-1081],[@b25-ijn-13-1081] As the effect of these AgNPs has been previously tested on murine lymphoma,[@b16-ijn-13-1081] one of the goals of this study was to assess whether the effect was similar in human cancer cell lines. To evaluate this effect on breast cancer cell lines, different molecular portraits were used. The behavior and prognosis of the disease depend, to a large extent, on the molecular presence of the estrogen receptor, progesterone receptor, HER2/neu status, and the genetic profile of the cell lines.[@b6-ijn-13-1081],[@b7-ijn-13-1081] Different molecular samples were included, as specified in the material and methods section, in order to observe the effect of AgNPs on these different cell lines.

We used xCELLigence -- an impedance-based live-cell monitoring platform -- to determine how AgNPs affect adhesion on breast cancer cell lines.[@b26-ijn-13-1081] Results are expressed in cell index, a complex measurement that can provide data with regard to cellular adhesion, viability, and proliferation;[@b26-ijn-13-1081] however, data displayed during the initial hours of the real-time assay essentially showed cellular adhesion.[@b27-ijn-13-1081],[@b28-ijn-13-1081] The decrease of the cell index caused by AgNPs represents a decrease in cell migration and metastasis of cancerous cells.[@b29-ijn-13-1081] The fact that the greatest decrease was observed in HCC70 shows the potential use of this nanomaterial as a treatment for triple-negative breast cancer, which is commonly associated with a worse prognosis. Although the mechanism of action by which AgNPs produce this effect has not yet been described, it is hypothesized that they affect focal adhesion kinases.[@b27-ijn-13-1081],[@b28-ijn-13-1081] These are large complexes of dynamic macromolecular proteins commonly found on migratory cells that provide the mechanical link between the cell and its binding to the extracellular matrix.[@b28-ijn-13-1081],[@b29-ijn-13-1081] Reported data from 9 to 24 hours of exposure to AgNPs can be used as an indicator of proliferation and cytotoxicity.[@b28-ijn-13-1081] Our data showed a clear decrease in the cell index in all lines, which proves their antiproliferative effect.

Previous studies within our study group showed that these AgNPs have antiproliferative and apoptotic effects and they, moreover, increase the production of reactive oxygen species (ROS) at concentrations of 9.0 µg/mL or higher in the L5178Y lymphoma cell line.[@b16-ijn-13-1081] The proliferation/viability assay by reduction of MTT to formazan crystals showed that AgNPs decrease the proliferation of breast cancer cell lines when compared to the control group -- except in the HCC1954 cell line, which in this test, did not show significant differences. The mechanism by which AgNPs generate this reduction in proliferation has not been well described. Asharani et al in 2009 proposed three possible mechanisms: 1) chromosomal aberrations, 2) DNA oxidation, and 3) cytoskeletal damage. Furthermore, the increase in ROS and DNA fracture in several studies has been confirmed so far.[@b11-ijn-13-1081],[@b14-ijn-13-1081],[@b30-ijn-13-1081]--[@b33-ijn-13-1081] The MTT assay did not provide the cause by which AgNPs decrease proliferation, although it did demonstrate that they have an antiproliferative effect.

The apoptosis assay showed a clear proapoptotic effect on the AgNP-treated cell lines, regardless of breast cancer molecular portraits. However, this proapoptotic effect increased as the prognosis of the cell line worsened. HCC70, classified as triple negative and the cell line with the worst prognosis in this study, showed the greatest apoptotic effect.[@b6-ijn-13-1081],[@b7-ijn-13-1081] The effect of AgNPs on cells can be proven by antiproliferative and apoptotic effects. Studies conducted on MDA-MB-231 and MCF-7 breast cancer lines have shown that exposure to AgNPs of different size and origin can cause caspase-3 activation, reduced expression of Bcl-2, and fragmentation of DNA that will eventually lead to apoptosis.[@b30-ijn-13-1081]--[@b32-ijn-13-1081] There is a difference in the effect of AgNPs shown by the assays of apoptosis and proliferation of HCC1954; this can be mostly explained because apoptosis was reported with the set of cells in early and late apoptosis. Cells in early stages of death could be considered viable cells by the MTT assay because they still have some mitochondrial activity and the number of cells undergoing proliferation could be compared to the number of cells in early and late apoptosis, as determined by Annexin V assay.[@b34-ijn-13-1081],[@b35-ijn-13-1081]

In order to assess how AgNPs affect adhesion, proliferation, and apoptosis, the genetic expression of cancer cell lines was analyzed. The expression analysis was only conducted in genes related to the biological tests undertaken in the study ([Figure 6](#f6-ijn-13-1081){ref-type="fig"}). There was a significant change in the expression of genes between the control and AgNP groups as some genes were overexpressed and others underexpressed in different patterns according to their molecular subtype.

Although knowing the expression values of different genes is useful, it does not provide enough information in its functional form. It has been postulated that a better way to systematically uncover gene function and the higher level organization of proteins into biological pathways is through the analysis of molecular interaction networks.[@b36-ijn-13-1081] In order to carry out this analysis, three different approaches have been proposed: 1) fixed-gene set enrichment analysis, 2) new network construction and clustering, and 3) network-based modeling.[@b37-ijn-13-1081] In this study, the third approach was mainly used in order to obtain a better understanding of the impact of genetic expression at the protein level, and it was undertaken with the PGM analysis and its different algorithms.[@b14-ijn-13-1081],[@b19-ijn-13-1081]

The 437 genes were processed using the PGM impact analysis, and an interactome was generated with the top 10% (122 nodes 248 edges).[@b21-ijn-13-1081] Then, they were grouped by modularity,[@b20-ijn-13-1081] and the resulting modules are shown in [Figure 7](#f7-ijn-13-1081){ref-type="fig"}. The size of the nodes is proportional to the PIS (the complete data of [Table 1](#t1-ijn-13-1081){ref-type="table"} is provided in the [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=152237.xlsx)). The interactome is not only a graphic representation of the PIS but also shows functional interactions in the genes involved. Some genes with significantly different protein impact, which have been associated as cancer bio-markers are *CCNB2*, *LAMA1*, *MMP3*, *SPARC*, *CKS2*, *BNIP2*, *IGFBP7*, *APC*, *LAMB3*, *LPL*, *COL8A1*, and *MTA1*. *CCNB2* has been primarily described as a marker in colorectal carcinoma; it upregulates and coordinates expression of other cell--cycle-related genes by NF-Y might contribute to tumor cell proliferation.[@b38-ijn-13-1081] *LAMA1* promotes cell adhesion, invasion, and migration of tumor and endothelial cells, resulting in tumor growth, angiogenesis, and metastasis.[@b39-ijn-13-1081] *MMP3* can cause epithelial--mesenchymal transition and malignant transformation in cultured cells.[@b40-ijn-13-1081] *SPARC* is overexpressed in many cancers, including breast cancer, and the effects of *SPARC* seem to be cell-type specific,[@b26-ijn-13-1081] as it can induce MMP-2 activation in two invasive breast cancer cell lines (MDA-MB-231 and BT549), but not in a noninvasive counterpart (MCF-7) which lacks MT1-MMP.[@b29-ijn-13-1081] *BNIP3* and *BNIP2* have been correlated with cell death and necrosis; these genes are underexpressed in breast cancer lines; however, after exposure to AgNPs, the values of the exposed lines seem to approach the values found in random samples.[@b41-ijn-13-1081] The available information on *IGFBP7* is controversial; it has been concluded that its alteration is related to cancer. However, depending on the cell line, this gene is either overexpressed or underexpressed.[@b42-ijn-13-1081],[@b43-ijn-13-1081] *APC* is an important tumor suppressor gene in breast cancer, and PIS values increase considerably after exposure to AgNPs.[@b44-ijn-13-1081] *LAMB3* -- a gene expressing the laminin protein known to influence cell differentiation, migration, adhesion, proliferation, and survival -- demonstrated in silencing studies that it functioned as an oncogene.[@b45-ijn-13-1081],[@b46-ijn-13-1081] *LPL* is associated with tumor nutrition and proliferation; its expression and activity varies in different types of cancer. *LPL* has high PIS values in untreated and AgNPs cell lines, although this is not so in random samples of the in silico analysis. This indicates that treatment with AgNPs does not normalize PIS; instead, it causes PIS to increase.[@b47-ijn-13-1081] The expression of COL8A1 is closely related to tumor cell proliferation, invasion, and tumorigenicity in vivo. However, treatment with AgNPs does not affect PIS values.[@b48-ijn-13-1081] MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers; nevertheless, PIS values of this gene are significantly lower than those in random samples generated by Reactome FIViz, and exposure to AgNPs does not seem to have any effect.[@b49-ijn-13-1081]

Using the enrichment analysis of the set of genes, we can understand the main routes that would be affected by these genes as those related to the extracellular matrix, such as extracellular matrix organization, focal adhesion, and integrin signaling pathway, and with respect to cell death, the intrinsic pathway for apoptosis and direct p53 effectors ([Table 2](#t2-ijn-13-1081){ref-type="table"}).

The PGM pathway analysis uses the PARADIGM algorithm to obtain an IPA score, where all significant data were related to components of the extracellular matrix, such as SPP1-CD44, PECAM1, SPP1, SPP1-Integrin alpha5beta1-alpha9beta1, SPP1-Integrin alphaVBeta1,3,5 and Integrin alphaVbeta3-PECAM1, that regulate cell communication, adhesion, and migration.[@b50-ijn-13-1081] Interaction of β1 integrins with hERG1 channels in cancer cells stimulated distinct signaling pathways that affect different aspects of tumor progression. However, the role of β1 integrins in tumorigenesis has not been fully resolved.[@b51-ijn-13-1081],[@b52-ijn-13-1081] Our data suggest that a lower IPA value increases the cell rate in breast cancer cell lines.

Results obtained in the two different PGM analyses do not show the same scope as in the biological assays related to adhesion, proliferation, and apoptosis. This could be due to the small sample or the absence of other additional data, such as those on methylations, polymorphisms, and copy number variations, which reduce the representability of RNA expression data.

Conclusion
==========

With these results, we can conclude that AgNPs possess a great therapeutic potential against cancer, by decreasing adhesion and proliferation and increasing the percentage of apoptosis. In addition, some genes by which AgNPs carry out their action were identified. However, more studies that focus on the mechanisms of action are needed before AgNPs can be safely used in the clinical setting.
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![The flow chart of the whole analysis in this study.\
**Abbreviation:** PGM, probabilistic graphical model.](ijn-13-1081Fig1){#f1-ijn-13-1081}

![Characterization of AgNPs. (**A**) Ultraviolet--visible spectra of AgNPs. (**B**) Transmission electron microscopy of AgNPs. (**C**) Histogram of the size of the particles.\
**Abbreviations:** AgNPs, silver nanoparticles; AU, arbitrary unit.](ijn-13-1081Fig2){#f2-ijn-13-1081}

![Adhesion analysis in real time: presented as mean and standard deviation; differences were calculated using Mann--Whitney *U*-test *p*\<0.05 (\*). MCF7 (**A**), HCC1954 (**B**), and HCC70 (**C**) cell lines.\
**Abbreviation:** AgNPs, silver nanoparticles.](ijn-13-1081Fig3){#f3-ijn-13-1081}

![Proliferation and viability: presented as mean and standard deviation; differences were calculated by the Student's *t*-test. *P*\<0.01 (\*\*).\
**Abbreviation:** AgNPs, silver nanoparticles.](ijn-13-1081Fig4){#f4-ijn-13-1081}

![Determination of apoptosis: cells were stained with Annexin V-fluorescein isothiocyanate (FLl) and propidium iodide (FL2), and cell apoptosis was analyzed by flow cytometry. (**A**) Total apoptosis percentage presented as mean and standard deviation; differences were calculated by the Student's *t*-test. *P*\<0.01 (\*\*). (**B**--**D**) Dot plots representative of each cell line.\
**Abbreviation:** AgNPs, silver nanoparticles.](ijn-13-1081Fig5){#f5-ijn-13-1081}

![Gene expression heat map of 437 selected genes in each cell line.\
**Abbreviation:** AgNPs, silver nanoparticles.](ijn-13-1081Fig6){#f6-ijn-13-1081}

![MEN of protein impact score. (**A**) Control cell lines and (**B**) cell lines treated with AgNPs.\
**Abbreviations:** AgNPs, silver nanoparticles; MEN, minimal essential network.](ijn-13-1081Fig7){#f7-ijn-13-1081}
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PGM impact analysis

  Name        Control sample   Random sample   *p*-value   AgNPs sample   Random sample   *p*-value
  ----------- ---------------- --------------- ----------- -------------- --------------- -----------
  ADAM23      2.426            1.773           0.152       2.186          1.589           0.108
  APC         0.85             1.794           0.014       1.514          1.609           0.724
  APEX1       1.138            1.699           0.131       1.175          1.737           0.347
  ATR         1.184            1.839           0.096       1.351          1.636           0.357
  ATRX        0.959            1.598           0.074       0.995          1.737           0.052
  AURKB       1.179            1.808           0.048       1.64           1.728           0.969
  BAG1        1.205            1.719           0.337       1.228          1.647           0.141
  BBC3        1.214            1.754           0.337       1.461          1.719           0.583
  BCCIP       1.184            1.7             0.17        1.277          1.778           0.232
  BCL2L10     2.422            1.689           0.202       2.267          1.707           0.232
  BCL2L11     1.142            1.651           0.147       1.456          1.658           0.543
  BIRC6       1.12             1.795           0.034       1.387          1.682           0.468
  BNIP2       0.751            1.761           0.013       1.759          1.837           0.86
  CASP4       2.301            1.667           0.084       1.753          1.709           0.953
  CASP5       2.248            1.648           0.057       1.737          1.677           0.875
  CCNA2       1.068            1.679           0.217       1.332          1.679           0.695
  CCNB2       0.237            1.775           3.70E-03    1.428          1.681           0.444
  CCNC        1.144            1.67            0.121       0.86           1.688           0.068
  CDC16       1.196            1.786           0.062       1.197          1.602           0.239
  CDC25C      1.173            1.756           0.347       1.062          1.601           0.152
  CDH1        2.537            1.693           0.117       2.977          1.773           7.65E-03
  CDH13       2.585            1.722           0.052       2.611          1.749           0.024
  CDH6        2.423            1.745           0.149       2.697          1.77            0.016
  CHD4        1.257            1.759           0.141       1.556          1.618           0.922
  CKS2        0.529            1.771           0.012       1.26           1.602           0.377
  CNTN1       2.253            1.698           0.039       1.82           1.819           0.937
  COL14A1     2.536            1.723           0.099       2.527          1.703           0.031
  COL15A1     2.305            1.749           0.121       2.429          1.645           0.02
  COL1A1      2.28             1.62            0.121       2.288          1.854           0.141
  COL4A2      2.445            1.592           0.039       7.09E-05       4.30E-05        0.05
  COL6A1      2.465            1.69            0.045       2.586          1.577           0.011
  COL8A1      2.46             1.643           0.021       2.543          1.716           0.029
  COX5A       0.982            1.609           0.081       1.32           1.693           0.158
  CRY1        1.311            1.811           0.29        1.264          1.695           0.239
  CSNK2A2     1.263            1.75            0.17        0.998          1.675           0.088
  CTBP1       1.129            1.77            0.084       1.197          1.772           0.141
  CTGF        2.2              1.623           0.065       2.673          1.593           0.013
  CUL1        0.904            1.732           0.045       1.271          1.648           0.421
  CXCL1       2.58             1.752           0.023       2.048          1.665           0.399
  CXCR4       2.646            1.636           0.136       2.513          1.588           0.052
  CYCS        1.104            1.716           0.176       1.925          1.671           0.41
  DKC1        0.808            1.658           0.039       0.801          1.745           0.036
  EDN1        2.488            1.727           0.096       2.258          1.64            0.176
  ERCC1       1.209            1.742           0.121       1.065          1.704           0.057
  ESR1        1.12             1.63            0.176       1.781          1.79            0.596
  F3          2.692            1.687           0.043       1.955          1.648           0.505
  FANCA       1.074            1.58            0.377       1.485          1.695           0.468
  FANCD2      0.96             1.747           0.033       1.246          1.739           0.141
  FLT4        1.121            1.911           0.024       2.163          1.771           0.317
  GADD45A     1.131            1.62            0.317       1.579          1.771           0.48
  GSTP1       2.184            1.553           0.202       1.045          1.761           0.041
  GTSE1       1.103            1.739           0.136       1.851          1.718           0.799
  HPSE        2.388            1.708           0.176       2.248          1.7             0.117
  HRAS        0.901            1.576           0.065       1.837          1.682           0.754
  HRK         2.3              1.686           0.176       2.763          1.67            0.016
  ICAM1       1.309            1.839           0.388       1.635          1.616           0.754
  IGFBP7      2.865            1.811           0.014       2.359          1.733           0.202
  IL18        2.618            1.764           0.048       1.717          1.564           0.922
  IL1B        2.259            1.701           0.074       2.818          1.685           7.21E-03
  ITGA4       2.643            1.64            0.027       2.229          1.715           0.317
  ITGAM       1.055            1.704           0.071       1.617          1.657           0.906
  ITGB3       1.171            1.668           0.299       2.388          1.706           0.05
  JAG1        2.177            1.631           0.108       2.385          1.761           0.099
  KISS1R      2.497            1.811           0.17        1.897          1.715           0.739
  KRT14       2.695            1.703           0.045       2.514          1.63            0.024
  KRT5        2.723            1.737           0.034       2.276          1.62            0.121
  LAMA1       2.584            1.631           6.04E-03    2.49           1.688           0.024
  LAMA2       2.241            1.653           0.117       1.346          1.649           0.308
  LAMA3       2.454            1.615           0.074       1.709          1.651           0.953
  LAMB3       2.57             1.679           0.018       2.236          1.686           0.131
  LEP         0.765            1.704           0.036       1.075          1.73            0.055
  LPL         2.847            1.8             0.02        3.047          1.714           6.04E-03
  MAP2K3      1.126            1.766           0.078       1.241          1.724           0.164
  MCL1        1.115            1.651           0.152       1.357          1.669           0.347
  MCM2        1.128            1.789           0.264       1.311          1.751           0.232
  MLH1        0.968            1.783           0.065       0.593          1.759           8.59E-03
  MMP1        2.303            1.72            0.141       2.022          1.743           0.377
  MMP13       2.539            1.702           0.084       2.514          1.604           0.057
  MMP15       0.885            1.661           0.152       0.966          1.633           0.124
  MMP3        2.703            1.723           0.029       2.931          1.759           4.19E-03
  MMP7        3.075            1.579           6.41E-03    2.354          1.641           0.141
  MSH2        1.067            1.676           0.196       1.023          1.747           0.028
  MTA1        0.937            1.761           0.022       0.909          1.719           0.028
  MYC         0.912            1.652           0.045       1.043          1.905           0.041
  NOTCH1      1.254            1.751           0.29        1.069          1.826           0.05
  OCLN        2.433            1.587           0.117       2.984          1.649           5.69E-03
  PECAM1      2.311            1.687           0.182       2.36           1.772           0.126
  PFKL        1.05             1.786           0.041       1.915          1.672           0.439
  PMS1        1.182            1.687           0.255       1.039          1.811           0.074
  PNKP        1.027            1.794           0.029       1.879          1.736           0.61
  RAD17       0.904            1.712           0.06        1.65           1.71            0.891
  RAD50       0.845            1.681           0.022       1.625          1.607           0.906
  RAD51       1.196            1.72            0.224       1.156          1.691           0.224
  RBBP8       1.255            1.771           0.377       1.906          1.705           0.583
  REV1        1.007            1.72            0.084       1.36           1.711           0.264
  RIPK2       2.256            1.7             0.202       1.822          1.653           0.638
  S1PR1       2.463            1.718           0.068       2.055          1.689           0.213
  SELE        2.276            1.734           0.126       1.454          1.783           0.255
  SERPINF1    2.298            1.712           0.131       2.613          1.685           7.21E-03
  SGCE        2.191            1.599           0.088       2.213          1.584           0.232
  SNAI1       1.202            1.76            0.281       1.849          1.781           1
  SOD1        1.104            1.686           0.096       1.451          1.754           0.337
  SPARC       3.026            1.711           7.21E-03    3.077          1.702           5.36E-03
  SPHK1       1.148            1.681           0.247       1.536          1.771           0.41
  SRC         1.258            1.798           0.399       1.607          1.75            0.739
  SSTR2       2.149            1.633           0.119       2.104          1.67            0.57
  SUMO1       1.225            1.782           0.152       1.804          1.626           0.638
  TBX2        2.356            1.715           0.078       2.139          1.663           0.192
  TFF3        2.369            1.738           0.114       2.737          1.847           0.033
  TGFB2       2.593            1.722           0.062       2.084          1.717           0.299
  THBS2       2.771            1.772           0.06        3.078          1.601           5.36E-03
  TIMP1       2.199            1.521           0.272       1.805          1.671           0.754
  TIMP3       2.491            1.542           0.022       1.96           1.747           0.596
  TNFRSF11B   2.362            1.786           0.182       2.062          1.61            0.224
  TNFRSF1A    1.005            1.6             0.078       1.102          1.679           0.108
  TP73        2.275            1.731           0.074       2.165          1.729           0.17
  TRAF2       1.066            1.714           0.068       0.653          1.702           0.013
  VCAM1       2.525            1.654           0.034       2.139          1.724           0.543
  VCAN        2.496            1.663           0.048       2.29           1.624           0.041
  VEGFC       2.325            1.568           0.055       2.197          1.759           0.299
  XBP1        2.611            1.623           0.033       2.43           1.788           0.131

**Note:** *p*≤0.05, FDR≤0.05.

**Abbreviations:** PGM, probabilistic graphical models; AgNPs, silver nanoparticles; FDR, false discovery rate.

###### 

Pathways identified in modules

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Module   Number of genes   Genes                                                                                                                                                                                                              Protein from module   Gene set-pathway                                           *p*-value   FDR
  -------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------- ---------------------------------------------------------- ----------- -----------
  0        25                *APC*, *AURKB*, *BAG1*, *BIRC6*, *BNIP2*, *CCNC*, *CDC16*, *CHD4*, *CNTN1*, *CRY1*, *CSNK2A2*, *CUL1*, *GSTP1*, *JAG1*, *LPL*, *MTA1*, *NOTCH1*, *OCLN*, *PFKL*, *PNKP*, *REV1*, *SNAI1*, *SOD1*, *SUMO1*, *UBC*   6\                    Signaling by NOTCH1\                                       5.99E-09\   1.17E-06\
                                                                                                                                                                                                                                                4\                    APC/C-mediated degradation of cell-cycle proteins\         4.59E-05\   2.99E-03\
                                                                                                                                                                                                                                                3                     Circadian clock                                            4.44E-04    0.017

  1        20                *COL14A1*, *COL15A1*, *COL1A1*, *COL4A2*, *COL6A1*, *COL8A1*, *CTGF*, *FLT4*, *IGFBP7*, *ITGA4*, *ITGAM*, *ITGB3*, *LAMA1*, *LAMA2*, *SPARC*, *TGFB2*, *THBS2*, *VCAM1*, *VCAN*, *VEGFC*                           15\                   Extracellular matrix organization\                         1.11E-16\   1.20E-14\
                                                                                                                                                                                                                                                10\                   Focal adhesion\                                            1.80E-12\   9.69E-11\
                                                                                                                                                                                                                                                9                     Integrin signaling pathway                                 7.31E-12    1.97E-10

  2        15                *ATR*, *ATRX*, *CTBP1*, *ERCC1*, *FANCA*, *FANCD2*, *MCM2*, *MLH1*, *MSH2*, *PMS1*, *RAD17*, *RAD50*, *RAD51*, *RBBP8*, *SSTR2*                                                                                    6\                    BARD1 signaling events\                                    8.84E-13\   5.92E-11\
                                                                                                                                                                                                                                                5\                    ATM pathway\                                               5.15E-10\   8.68E-09\
                                                                                                                                                                                                                                                5                     ATR signaling pathway                                      7.84E-10    1.02E-08

  3        13                *APEX1*, *CCNB2*, *CDC25C*, *CKS2*, *COX5A*, *CYCS*, *EDN1*, *ESR1*, *GADD45A*, *GTSE1*, *ICAM1*, *MYC*, *TBX2*                                                                                                    4\                    p53 signaling pathway\                                     9.32E-07\   1.64E-04\
                                                                                                                                                                                                                                                4\                    Cell cycle\                                                9.95E-06\   7.52E-04\
                                                                                                                                                                                                                                                3                     FOXM1 transcription factor network                         1.39E-05    7.52E-04

  4        11                *CXCL1*, *CXCR4*, *HRAS*, *MAP2K3*, *PECAM1*, *RIPK2*, *S1PR1*, *SPHK1*, *SRC*, *TNFRSF1A*, *TRAF2*                                                                                                                4\                    PDGFR-beta signaling pathway\                              5.89E-06\   4.42E-04\
                                                                                                                                                                                                                                                3\                    CXCR3-mediated signaling events\                           6.51E-06\   4.42E-04\
                                                                                                                                                                                                                                                3                     TNF receptor signaling pathway                             1.47E-05    7.92E-04

  5        11                *CDH1*, *CDH13*, *LAMA3*, *LAMB3*, *MMP1*, *MMP13*, *MMP15*, *MMP3*, *MMP7*, *TIMP1*, *TIMP3*                                                                                                                      9\                    Extracellular matrix organization\                         1.54E-13\   1.05E-11\
                                                                                                                                                                                                                                                3\                    Plasminogen activating cascade\                            1.12E-07\   2.47E-06\
                                                                                                                                                                                                                                                4                     Cell junction organization                                 7.01E-07    1.19E-05

  6        5                 *BBC3*, *BCL2L11*, *CCNA2*, *MCL1*, *TP73*                                                                                                                                                                         3\                    Direct p53 effectors\                                      2.07E-05\   2.90E-04\
                                                                                                                                                                                                                                                2\                    Intrinsic pathway for apoptosis p53 signaling pathway      1.23E-04\   1.23E-03\
                                                                                                                                                                                                                                                2                                                                                4.37E-04    3.50E-03

  7        2                 *KRT14*, *KRT5*                                                                                                                                                                                                    2\                    Validated transcriptional targets of deltaNp63 isoforms\   2.03E-05\   4.06E-05\
                                                                                                                                                                                                                                                2                     Glucocorticoid receptor regulatory network                 5.83E-05    5.83E-05
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** *p*≤0.05, FDR≤0.05.

**Abbreviation:** FDR, false discovery rate.

###### 

PGM pathway analysis

  Pathway     Name: Functional components \[localization\]\_Reactome Identification number.   IPA AgNPs   IPA control   *p*-value   FDR
  ----------- ------------------------------------------------------------------------------- ----------- ------------- ----------- -------
  Adherence   SPP1:CD44 \[plasma membrane\]\_2752110                                          −2.713      −0.591        3.95E-03    0.047
  Adherence   PECAM1 \[plasma membrane\]\_114686                                              −1.034      0.865         3.95E-03    0.047
  Adherence   SPP1 \[extracellular region\]\_215967                                           −2.227      −0.477        3.95E-03    0.047
  Adherence   SPP1:Integrin alpha5beta1, alpha9beta1 \[plasma membrane\]\_265417              −2.227      −0.641        3.95E-03    0.047
  Adherence   SPP1:Integrin alphaVBeta1,3,5 \[plasma membrane\]\_2752132                      −2.227      −0.641        3.95E-03    0.047
  Adherence   Integrin alphaVbeta3:PECAM1 \[plasma membrane\]\_210229                         −1.793      −0.37         3.95E-03    0.047
  Adherence   Integrin alphaVbeta3:Tenascin \[plasma membrane\]\_265412                       −1.723      −0.585        3.95E-03    0.047
  Adherence   TNC \[extracellular region\]\_215968                                            −0.964      −0.07         3.95E-03    0.047
  Adherence   Tenascin-C hexamer \[extracellular region\]\_216010                             −0.964      −0.07         3.95E-03    0.047
  Adherence   Integrin alpha9beta1:Tenascin-C hexamer \[plasma membrane\]\_216014             −0.964      −0.315        3.95E-03    0.047
  Adherence   Integrin alpha2bbeta3:FN1(32-2386) \[plasma membrane\]\_349592                  −1.951      −0.63         0.025       0.125
  Adherence   FN1(32-2386) \[extracellular region\]\_54851                                    −1.197      −0.117        0.025       0.125
  Adherence   Integrin alpha2bbeta3 \[plasma membrane\]\_114514                               −1.064      −0.37         0.025       0.125
  Adherence   Integrin alpha IIb beta 3:Fibrin complex \[plasma membrane\]\_114559            −1.064      −0.37         0.025       0.125
  Adherence   Integrin alphaVbeta3 \[plasma membrane\]\_210216                                −1.064      −0.37         0.025       0.125
  Adherence   Integrin alphaIIbbeta3:VWF multimer \[plasma membrane\]\_216031                 −1.064      −0.37         0.025       0.125
  Adherence   Integrin alphaVbeta3:IBSP \[plasma membrane\]\_265408                           −1.064      −0.37         0.025       0.125
  Adherence   Integrin alphaVbeta3:VWF multimer \[plasma membrane\]\_265414                   −1.064      −0.37         0.025       0.125
  Adherence   Integrin alphaVbeta3:Fibrillin-1 \[plasma membrane\]\_265416                    −1.064      −0.37         0.025       0.125
  Adherence   Integrin alphaIIbbeta3:THBS1 \[plasma membrane\]\_349605                        −1.064      −0.37         0.025       0.125
  Adherence   Tetrastatin:Integrin alphaVbeta3 \[plasma membrane\]\_4088257                   −1.064      −0.37         0.025       0.125
  Adherence   Integrins alphaVbeta3, alphaVbeta5 \[plasma membrane\]\_4085079                 −0.282      0.178         0.025       0.125
  Adherence   Integrin alphaMbeta2 \[plasma membrane\]\_202755                                0.357       −0.182        0.025       0.125
  Apoptosis   CTNNB1-1(1--115) \[cytosol\]\_202930                                            −0.59       0.00E+00      3.95E-03    0.292
  Apoptosis   CTNNB1-1(116--376) \[cytosol\]\_202950                                          −0.59       0.00E+00      3.95E-03    0.292
  Apoptosis   CASP8(1--479) \[cytosol\]\_57031                                                −0.29       0.386         0.025       0.337
  Apoptosis   CASP8(1--479) \[cytosol\]\_57031                                                −0.29       0.386         0.025       0.25
  Apoptosis   CASP8(1--479) \[cytosol\]\_57031                                                −0.29       0.386         0.025       0.337
  Apoptosis   Active caspase-8 \[cytosol\]\_2562550                                           −0.48       0.386         0.025       0.673
  Apoptosis   Active caspase-8 \[mitochondrial outer membrane\]\_2671818                      −0.48       0.386         0.025       0.673
  Apoptosis   OCLN \[plasma membrane\]\_351846                                                1.783       1.13          0.025       0.673
  Apoptosis   CASP8(1--479) \[cytosol\]\_57031                                                −0.29       0.386         0.025       0.25

**Note:** *p*≤0.05, FDR≤0.05.

**Abbreviations:** PGM, probabilistic graphical models; IPA, integrated pathway activity; AgNPs, silver nanoparticles; FDR, false discovery rate.
